Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.68 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30249436 | 1.00 | CYP4F2 (0.68) | CYP4F2CYP4A11HPGDTHRBHTT | |
| SCHEMBL3846563 | 0.87 | CYP4F2 (0.55) | CYP4F2CYP4A11HPGDTHRBHTT | |
| SCHEMBL27715049 | 0.84 | HPGD (0.67) | CYP4F2CYP4A11HPGDTHRBHTT | |
| SCHEMBL234030 | 0.84 | TSHR (0.60) | CYP4F2CYP4A11HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL17022287 | 0.83 | ALDH1A1 (0.55) | CYP4F2CYP4A11ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL11225504 | 0.83 | CYP4F2 (0.67) | CYP4F2CYP4A11HPGDALDH1A1KMT2A | |
| SCHEMBL2406530 | 0.83 | CYP4F2 (0.67) | CYP4F2CYP4A11HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL288615 | 0.83 | ALDH1A1 (0.55) | CYP4F2CYP4A11HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL29571295 | 0.83 | ALDH1A1 (0.55) | CYP4F2CYP4A11HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL2313707 | 0.81 | CA12 (0.70) | HPGDALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110827-B | Diamine, and preparation method and application thereof | 安徽国风新材料股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-112110827-A | Diamine, and preparation method and application thereof | 安徽国风塑业股份有限公司 | 2020-12-22 | — | — | CN | claimed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-3745105-B1 | TEMPERATURE DETECTION LABEL AND ARTICLE MANAGEMENT DEVICE USING SAME | HITACHI LTD (JP) | 2025-08-27 | — | — | EP | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20240400247-A1 | TEMPERATURE INDICATOR MANUFACTURING SYSTEM AND TEMPERATURE INDICATOR MANUFACTURING METHOD | HITACHI INDUSTRIAL EQUIPMENT SYSTEMS CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240351970-A1 | PREPARATION METHOD OF 5-BROMO-2-CHLORO-BENZOIC ACID AS A SYNTHETIC RAW MATERIAL FOR HYPOGLYCEMIC DRUGS | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2024-10-24 | — | — | US | disclosed |
| EP-4431889-A1 | TEMPERATURE INDICATOR MANUFACTURING SYSTEM AND TEMPERATURE INDICATOR MANUFACTURING METHOD | Hitachi Industrial Equipment Systems Co., Ltd. (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12085452-B2 | Temperature detection ink, temperature detection ink initialization method, temperature indicator, and article management system | HITACHI INDUSTRIAL EQUIPMENT SYSTEMS CO., LTD. (JP) | 2024-09-10 | — | — | US | disclosed |
| EP-3614113-B1 | TEMPERATURE DETECTING MATERIAL AND PRODUCT CONTROL METHOD | HITACHI INDUSTRY EQUIPMENT SYSTEMS CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024142146-A1 | TEMPERATURE INDICATOR AND METHOD FOR PRODUCING TEMPERATURE INDICATOR | 株式会社日立産機システム | 2024-07-04 | — | — | WO | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006044732-A2 | 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| US-6555541-B1 | P2X7 receptor antagonists for treatment of inflammatory respiratory system disorders such as asthma; for example, 2-(3,4-Difluorophenylamino)-N-(2-methyl-5-piperazin-1-yl-methyl-phenyl) -acetamide, trihydrochloride | ASTRAZENECA UK LIMITED (GB) | 2003-04-29 | — | — | US | disclosed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
| CN-1351598-A | Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions | ASTRAZENECA AB (SE) | 2002-05-29 | — | — | CN | disclosed |
| EP-1185522-A1 | SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000071529-A1 | SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS | ASTRAZENECA AB (SE) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | CYP4F2 4303/4885CYP4A11 3755/4885HPGD 3161/4885 |
| US-20240351970-A1 | PREPARATION METHOD OF 5-BROMO-2-CHLORO-BENZOIC ACID AS A SYNTHETIC RAW MATERIAL FOR HYPOGLYCEMIC DRUGS | GABRA5, DDC, GCG | CYP4F2 462/4885CYP4A11 484/4885HPGD 3766/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP4F2 2700/4885CYP4A11 1337/4885HPGD 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.